49 50

Cited 0 times in

The Korean Society for Neuro-Oncology (KSNO) Guideline for Glioblastomas: Version 2018.01

Authors
 Young Zoon Kim  ;  Chae-Yong Kim  ;  Jaejoon Lim  ;  Kyoung Su Sung  ;  Jihae Lee  ;  Hyuk-Jin Oh  ;  Seok-Gu Kang  ;  Shin-Hyuk Kang  ;  Doo-Sik Kong  ;  Sung Hwan Kim  ;  Se-Hyuk Kim  ;  Se Hoon Kim  ;  Yu Jung Kim  ;  Eui Hyun Kim  ;  In Ah Kim  ;  Ho Sung Kim  ;  Tae Hoon Roh  ;  Jae-Sung Park  ;  Hyun Jin Park  ;  Sang Woo Song  ;  Seung Ho Yang  ;  Wan-Soo Yoon  ;  Hong In Yoon  ;  Soon-Tae Lee  ;  Sea-Won Lee  ;  Youn Soo Lee  ;  Chan Woo Wee  ;  Jong Hee Chang  ;  Tae-Young Jung  ;  Hye Lim Jung  ;  Jae Ho Cho  ;  Seung Hong Choi  ;  Hyoung Soo Choi  ;  Je Beom Hong  ;  Do Hoon Lim  ;  Dong-Sup Chung 
Citation
 Brain Tumor Research and Treatment, Vol.7(1) : 1-9, 2019 
Journal Title
 Brain Tumor Research and Treatment 
ISSN
 2288-2405 
Issue Date
2019
Keywords
Glioblastomas ; Guideline ; Korean Society for Neuro-Oncology ; Practice
Abstract
BACKGROUND: There has been no practical guidelines for the management of patients with central nervous system (CNS) tumors in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, started to prepare guidelines for CNS tumors from February 2018. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified through searches of PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL using specific and sensitive keywords as well as combinations of keywords. RESULTS: First, the maximal safe resection if feasible is recommended. After the diagnosis of a glioblastoma with neurosurgical intervention, patients aged ≤70 years with good performance should be treated by concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide chemotherapy (Stupp's protocol) or standard brain radiotherapy alone. However, those with poor performance should be treated by hypofractionated brain radiotherapy (preferred)±concurrent or adjuvant temozolomide, temozolomide alone (Level III), or supportive treatment. Alternatively, patients aged >70 years with good performance should be treated by hypofractionated brain radiotherapy+concurrent and adjuvant temozolomide or Stupp's protocol or hypofractionated brain radiotherapy alone, while those with poor performance should be treated by hypofractionated brain radiotherapy alone or temozolomide chemotherapy if the patient has methylated MGMT gene promoter (Level III), or supportive treatment. CONCLUSION: The KSNO's guideline recommends that glioblastomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to the individual comprehensive condition of the patient.
Files in This Item:
T201902526.pdf Download
DOI
10.14791/btrt.2019.7.e25
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Kang, Seok Gu(강석구) ORCID logo https://orcid.org/0000-0001-5676-2037
Kim, Se Hoon(김세훈) ORCID logo https://orcid.org/0000-0001-7516-7372
Kim, Eui Hyun(김의현) ORCID logo https://orcid.org/0000-0002-2523-7122
Yoon, Hong In(윤홍인) ORCID logo https://orcid.org/0000-0002-2106-6856
Chang, Jong Hee(장종희)
Cho, Jae Ho(조재호) ORCID logo https://orcid.org/0000-0001-9966-5157
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/170970
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse